Previous 10 | Next 10 |
home / stock / medi:cc / medi:cc news
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedel...
KGK has received approval from Health Canada for Phase II clinical trial to test the efficacy of psilocybin on Fragile X syndrome Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), a...
The Research License greatly reduces the timelines required for conducting cannabis research as it eliminates the need for obtaining a project specific cannabis research license Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: ...
A randomized, triple-blind, placebo-controlled clinical trial involving supplementation with a bioflavonoid ingredient UP446 provides evidence for a robust, healthy immune response in healthy adults following influenza vaccination. Wellbeing Digital Sciences Inc. (“ Wellbeing...
KGK has submitted a clinical trial application for Phase IIa clinical trial to test the efficacy of psilocybin on Fragile X syndrome Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 )...
Clinic reaches patient milestone in less than two years since being acquired by Wellbeing Digital Sciences Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidenc...
Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, includin...
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including...
KGK to conduct Phase II clinical trial to test the efficacy of psilocybin on Fragile X syndrome Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based men...
Gefion Canada GT4 technology was used to deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volunteers in the form of a topical cream applied to the skin Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (N...
News, Short Squeeze, Breakout and More Instantly...
WELLBEING DIGITAL SCIENCES INC. Company Name:
MEDI:CC Stock Symbol:
AQNC Market:
WELLBEING DIGITAL SCIENCES INC. Website:
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedel...
Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) ( NEO: MEDI ) ( OTC: KONEF ) ( FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psych...
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedel...